Abstract
The goal of antiarrhythmic therapy in patients with ventricular premature beats or runs of ventricular tachycardia is usually aimed at preventing dysrhythmia induced death rather than alleviating symptomatology. The major dilemma facing the clinician is that the use of easily quantifiable total or partial pharmacologic suppression of ventricular arrhythmia during a period of electrocardiographic monitoring has not been shown to be associated with a subsequent reduction in the risk of dysrhythmic deaths. Thus, it is appropriate to consider whether sudden death can be adequately identified as a dysrhythmic event so that it can be used as an end-point for a clinical trial evaluating antiarrhthymic agents.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Graboys TB, Lown B, Podrid RJ, DeSilva R: Long-term survival of patients with malignant ventricular arrhythmia treated with antiarrhythmic drugs. Am J Cardiol 50: 437–443, 1982.
Hinkle LE, Thaler HT: Clinical classification of cardiac deaths. Circulation 65: 457–464, 1982.
Epstein SE, Palmere ST, Patterson RE. Evaluation of patients after acute myocardial infarction. N Engl J Med 50: 437–443, 1982.
Weaver WD, Cobb LA, Hallstrom AP: Ambulatory arrhythmias in resuscitated victims of cardiac arrest. Circulation 66: 212–218, 1982.
Goldstein S, Landis R, Leighton R, Ritter G, Vasu M, Lantis A, Serokman R: Characteristics of the resuscitated out-of-hospital cardiac arrest victim with coronary heart disease. Circulation 64: 977–984, 1981.
Ruberman W, Weinblatt E, Goldberg JD, Frank CW, Shapiro S: Ventricular premature beats and mortality after myocardial infarction. New Engl J Med 297: 750–757, 1984.
Schaffer WA, Cobb LA: Recurrent ventricular fibrillation and modes of death in survivors of out-of-hospital ventricular fibrillation. N Engl J Med 293: 259–262, 1975.
Cohn JN, Levine TB, Oliveri MT, Garberg V, Lura D, Francis GS, Simon AB, Rector T: Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med 311: 819–823, 1984.
Franciosa JA, Wilen M, Ziesche S, Cohn JN: Survival in men with severe chronic left ventricular failure due to either coronary heart disease or idiopathic diluted cardiomyopathy. Am J Card 51: 831–836, 1983.
Hamer AWF, Peter T, Weiss D, Mandel WJ: The empirical use of chronic oral amiodarone therapy to prevent recurrent, sudden cardiac death. New Aspects in the Medical Treatment of Tachyarrhythmias, Breithardt G and Loogen F (eds.), Urban and Schwarzenberg, 1983, 153–157.
Bacaner MB, Benditt DG: Antiarrhythmic, antifibrillatory, and hemodynamic actions of bethanidine sulfate: an orally effective analog of bretylium for suppression of ventricular tachyarrhythmias. Am J Cardiol 50: 728–734, 1982.
Beta-blocker Heart Attack Trial Research Group: A randomized trial of propranolol in patients with acute myocardial infarction. I. Mortality Results. JAMA 247: 1707–1714, 1982.
Swerdlow CD, Winkle RA, Mason JW: Determinants of survival in patients with ventricular tachyarrhythmias. N Eng J Med 308: 1436–1442.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1985 Martinus Nijhoff Publishing, Boston
About this chapter
Cite this chapter
Cohn, J.N., Rector, T. (1985). Sudden Death as an End-Point for the Clinical Evaluation of Antiarrhythmic Drugs. In: Morganroth, J., Moore, E.N. (eds) Cardiac Arrhythmias: New Therapeutic Drugs and Devices. Developments in Cardiovascular Medicine, vol 47. Springer, Boston, MA. https://doi.org/10.1007/978-1-4613-2595-6_13
Download citation
DOI: https://doi.org/10.1007/978-1-4613-2595-6_13
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4612-9626-3
Online ISBN: 978-1-4613-2595-6
eBook Packages: Springer Book Archive